Studies have shown that active fund managers routinely underperform the S&P500 index*​

Chemomab Therapeutics Ltd. (NASDAQ: CMMB)

CMMB Stock Predictions and Ratings

WSX Rating:
NOT AVAILABLE
WSX Forecast (1yr):
NOT AVAILABLE
Analyst Rating:
BUY
Analyst Forecast (1yr):
400%

CMMB Stock Analysis

CMMB PE Ratio:

CMMB PEG Ratio: Not Available

CMMB Forward EPS Growth (12 month): 0.00%

CMMB PS Ratio:

CMMB PSG Ratio: Not Available

CMMB Forward Revenue Growth (12 month): 0.00%

CMMB Articles

No data was found